GSMA
25.4.2018 10:02:10 CEST | Business Wire | Press release
The GSMA will celebrate the annual ITU International Girls in ICT Day this week with a series of events across its global footprint aimed at encouraging and empowering young women to explore career opportunities in the science, technology, engineering and mathematics (STEM) areas and helping companies worldwide reap the benefits of greater female participation in the tech sector. The 2018 ITU International Girls in ICT Day will be held on Thursday 26 April and will be marked by events run by local GSMA offices in Atlanta, Barcelona, Brussels, Dubai, Hong Kong, London and Nairobi.
“The GSMA is delighted to be supporting the ITU International Girls in ICT event for the fifth year running, inviting girls from around the world to learn about the rewarding careers possible within the mobile industry and the wider ICT sector,” said Mats Granryd, Director General, GSMA. “The future success of our industry rests on the ability to attract talented females and we hope to inspire a new generation of young women to become tomorrow’s industry leaders.”
At its global headquarters in London, the GSMA is inviting a group of girls from The Bridge Academy, a school in the London borough of Hackney, to an event hosted by BT at its innovation event space. The girls will take part in a problem-solving challenge and try out speed networking with successful women in the tech industry. Speakers at the London event will include representatives from Arsenal FC, Cambridge University, Mastercard and Vodafone.
Other related events include:
- Atlanta: In partnership with Cricket Wireless, the North America team will be donating mobile phones with prepaid data and messaging plans to girls that attended an earlier coding workshop with ChickTeck Atlanta .
- Barcelona: In partnership with Telefónica, WAYRA (Telefónica Open Future start-up accelerator programme) and Mobile World Capital Barcelona, the GSMA Spanish office has invited local girls to hear from industry experts and entrepreneurs and participate in a hands-on design and technology workshop.
- Brussels: The day will be marked as part of the Women4Tech event in Brussels this week, featuring high-level speakers from the European Commission.
- Hong Kong: The local GSMA office will be hosting a group of 10 girls for a half-day event on Saturday 28 April, teaching them how to code followed by a number of guest speakers.
- Dubai: Local GSMA representatives are inviting girls to the offices of several national ICT Ministries followed by tours of local operators, including Umniah in Jordan; MTN, Sudatel and Zain in Sudan; and Ooredoo, Orange and Tunisie Telecom in Tunisia.
- Nairobi: The GSMA local office is working with local primary and secondary schools to host a day featuring representatives from the mobile and tech industries.
Supporting the Sustainable Development Goals
Participation in initiatives such as the ITU International Girls in ICT Day underlines the mobile industry’s commitment to helping to achieve the United Nations Sustainable Development Goals (SDGs), particularly SDG 5 (Gender Equality), SDG 4 (Quality Education), SDG 8 (Decent Work and Economic Growth) and SDG 10 (Reduced Inequalities).
The GSMA is a Topic Chair of the W20 (Women 20) group, which will advise the G20 member states on issues around gender equality and the economic empowerment of women in the run-up to the G20 Argentina 2018 summit taking place in Buenos Aires, 30 November – 1 December 20181 .
The GSMA also supports gender equality and opportunities for women and girls via its participation in the EQUALS initiative; the GSMA Connected Women programme; Women4Tech ; the WeCare initiative in Latin America; and the #BetterFuture campaign.
-ENDS-
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.
For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA .
View source version on businesswire.com: https://www.businesswire.com/news/home/20180425005130/en/
Contact:
For the GSMA
Beau Bass
+44 79 7662 4962
beau.bass@webershandwick.com
GSMA
Press Office
pressoffice@gsma.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom